Enhancing Burn Care with MolecuLight at the American Burn Association 2025
MolecuLight Inc., a global leader in fluorescence imaging technology for rapid bacterial detection in wounds, is making significant strides in burn care at the 2025 American Burn Association (ABA) Annual Meeting held in Phoenix, Arizona, from April 8 to April 11. The focus of this meeting is on the innovative solutions that can improve the healing process for burn victims.
During the conference, MolecuLight will demonstrate their groundbreaking fluorescence imaging systems that provide immediate, non-invasive visualization of bacterial presence in wounds. This capability allows healthcare providers to make informed decisions in real time, ultimately optimizing the management of burn injuries.
Key Presentations and Innovations
Attendees will have the unique opportunity to witness several critical presentations that highlight the advancements in clinical practices surrounding burn care. Dr. Erik Hanson-Viana, a prominent plastic and reconstructive surgeon from Hospital Ángeles in Mexico City, will share his research on the benefits of fluorescence-guided sampling. He is scheduled to present on April 9 at 11:45 AM during the educational forums session. His findings illustrate how the MolecuLight-guided approach surpasses traditional techniques, allowing for improved timing and placement of skin grafts in the treatment of large burns.
Moreover, Dr. Carlos Daniel Torres García, a resident in plastic surgery at Hospital Ángeles, will present his award-winning research at the poster session on the same day, at 12:30 PM. His study, titled "Bacterial Fluorescence Signals Correlate with Infection in Dermal Regeneration Template in Burn Patients," emphasizes the critical connection between detected bacterial loads using MolecuLight technology and the outcomes of cellular tissue products in burn reconstruction. His work has gained international recognition, winning second place for Best Scientific Protocol at the 55th National Plastic Surgery Congress earlier this year.
Live Demonstrations
To enhance understanding of their advanced imaging systems, MolecuLight will host live demonstrations at booth number 626 throughout the conference. Attendees will have the chance to interact with Dr. Hanson-Viana and other experts from MolecuLight, observing firsthand how the MolecuLight iX® and MolecuLight DX™ systems function. These demonstrations will showcase real-time data about bacterial loads that can inform clinical decision-making for superior burn care.
Dr. Hanson-Viana highlights the profound implications of real-time bacterial visualization for improving wound reconstruction, stating, "The ability to visualize bacteria in real time with MolecuLight leads to more precise interventions, ultimately enhancing reconstruction outcomes. My research clearly demonstrates the distinct advantage of MolecuLight-guided sampling over conventional methods, and I am eager to share these insights with my colleagues at the ABA meeting."
About MolecuLight Inc.
MolecuLight Inc. is a private, global imaging diagnostics company that develops and commercializes the MolecuLight iX® and DX™ imaging devices. These are currently the only FDA-approved Class II point-of-care imaging devices designed for real-time detection of elevated bacterial loads in wounds. In addition to bacterial detection, these devices provide accurate digital measurements of wounds for comprehensive treatment management, supported by robust clinical evidence, including over 100 peer-reviewed publications. For more information, visit
www.moleculight.com.